PRL-phosphatase inhibitor

PRL-phosphatase inhibitor is a proprietary small molecule lead compound being developed by Kanyr Pharma for the treatment of multiple cancers. It is designed to inhibit the Phosphatase of Regenerating Liver (PRL) family, which includes PRL-1, PRL-2, and PRL-3 (also known as Protein Tyrosine Phosphatase 4A or PTP4A1, PTP4A2, and PTP4A3). These dual-specificity phosphatases are highly oncogenic and are overexpressed in over 90% of all cancers, where they play critical roles in promoting tumor cell proliferation, growth, invasion, and metastasis. The drug candidate was originally developed at McGill University and was subsequently acquired by Kanyr Pharma. It is currently in preclinical development as a targeted therapy to block the progression and spread of various solid and hematological tumors.

Other names

PRL inhibitorPRL-1/2/3 inhibitorPTP4A inhibitorPTP-4A inhibitorPTP 4A inhibitorPRL-phosphatase lead compound